EUCTR2011-001539-21-DE进行中（未招募）1 期
A 2-arm, prospective, randomized, controlled, open-label, 12 month Phase III trial to evaluate the efficacy of Everolimus in combination with a centre specific standard immunosuppressive regimen consisting of CNI, MPA and steroids versus a standard triple immunosuppressive regimen in lung transplant recipients - 4EVERLUNG
ovartis Pharma GmbH0 个研究点开始时间: 2011年8月10日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Adult recipients of de novo cadaveric lung transplants older than 18 years, 3-18 months prior to enrolment
- •2.Patients with impaired (mild/moderate) renal function, i.e. GFR >50 and <90mL/min measured by CKD EPI prior inclusion, confirmed by two independent measurements
- •3.Patients able to take oral medication at time of randomization
- •4.Patients on a CNI-containing triple immunosuppressive regimen at time of randomization
- •5.Patients who are willing and able to participate in the study and from whom written informed consent has been obtained
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 172
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •1.Patients who are recipients of multiple solid organ or islet cell tissue transplants, or have previously received an organ or tissue transplant
- •2.Patients with pre-transplant immunosuppressive CNI- or everolimus containing treatment
- •3.Patients with renal failure or CKD/ESRD who require renal replacement therapy within 7 days prior to randomization or who required renal replacement therapy for clearance for more than 2 weeks prior to transplantation
- •4.Patients who are recipients of A-B-O incompatible transplant grafts
- •5.Patients with any known hypersensitivity to everolimus, mycophenolic acid, tacrolimus, cyclosporine A, steroids, other drugs similar to everolimus (e.g., macrolides), or other components of the formulations (e.g. lactose, see also SmPCs)
- •6.Patients who have received an investigational drug within 30 days prior to randomization
- •7.Two episodes of acute rejection that required antibody therapy or more than one steroid sensitive episode of acute rejection in the last 3 months prior to randomization. This includes patients who have not completed steroid treatment for acute rejection within 7 days prior to randomization
- •8.Patients receiving plasmaphoresis or immunomodulatory antibody treatment within 6 months prior to randomization
- •9.Patients with thrombocytopenia (platelets <100,000/mm³), with an absolute neutrophil count of <1,500/mm³ or leucopenia (leucocytes <3000/mm³), with anemia with Hb < 8g/dl at time of screening
- •10.Patients with uncontrolled hypercholesterolemia (>330mg/dL; >9mmol/L) or hypertriglyceridemia (>300 mg/dL; >8.5 mmol/L) at time of screening
- •11.Patients with a creatinine/protein ratio indicating daily urinary protein excretion >1g/24h at time of randomization
- •12.Patients with history of thrombotic microangiopathies
- •13.Patients with history of Burkholderia cepacia complex colonisation
- •14.Patients with BOS ( > grade 1) at time of randomization
- •15.Patients with history of inability to maintain to CNI target levels in more than 6 of the last 10 measurements according to investigator’s discretion.
- •16.Patients with symptoms of significant mental illness and with inability to cooperate or communicate with the investigator. Patients who are unlikely to comply with the study requirements, or who are unable to give informed consent
- •17.Patients with a history of malignancy of any organ system, treated or untreated, during the last five years, whether or not there is evidence of local recurrence or metastases, except squamous or basal cell carcinoma of the skin
- •18.Patients who are in a intensive care setting in the last 30 days before randomization
- •19. Patients who are HIV positive or Hepatitis B surface antigen positive or Hepatitis C (PCR+ only) virus positive
- •20.Patients with clinically significant systemic infection at time of randomization
- •21.Females who are pregnant or breast feeding (pregnancy defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/ml))
- •22.The reproductive-developmental toxicity profile of the study drug, the study design, and the study’s target population will guide the schedule for pregnancy tests to be performed throughout the study.
- •23.Women who are pregnant or breast feeding
- •24.Patients, who have already been randomized into this study earlier must not be included a second time
- •25.Evidence of unsolved drug or alcohol addiction
- •26.Study personne
研究者
相似试验
已完成
4 期
Study to assess efficacy & safety of doxofylline 400 mg twice daily versus doxofylline 800 mg ER once daily in the treatment of chronic obstructive pulmonary disease.CTRI/2008/091/000154German Remedies Division, Cadila Healthcare Limited
尚未招募
4 期
A prospective,randomized,double-blind,2-arm,active-controlled,parallel,multicentre,postmarketingclinical trial to assesstheefficacy andsafety ofRabeprazole SodiumEC Capsules20mg ascomparedtoconventionalRabeprazoleGastroResistantTablets IP20mg in patients with gastro-oesophageal reflux diseaseCTRI/2022/01/039744Zydus Healthcare Limited
已完成
不适用
A study to evaluate the efficacy and safety of Lipoxim Fire for weight management in overweight healthy womeISRCTN74656856INNOVATION LABO60
已完成
Unknown
Efficacy of OPTIMEALTH FOOD on Gut healthImprovement of constipation symptomsDigestive SystemISRCTN16659746INNOVATION LABO SCIENCES Co., Ltd60
已完成
2 期
Clinical study to evaluate and compare the immunogenicity and safety of Tetanus vaccine of Cadila Healthcare Ltd. vs Tetanus vaccine of Serum Institute of India Ltd. in healthy subjects and subjects with clean minor woundsCTRI/2015/05/005740Cadila Healthcare Ltd283